726 related articles for article (PubMed ID: 17264849)
1. Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial.
Eliasson B; Gudbjörnsdottir S; Cederholm J; Liang Y; Vercruysse F; Smith U
Int J Obes (Lond); 2007 Jul; 31(7):1140-7. PubMed ID: 17264849
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
Rosenstock J; Hollander P; Gadde KM; Sun X; Strauss R; Leung A;
Diabetes Care; 2007 Jun; 30(6):1480-6. PubMed ID: 17363756
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
[TBL] [Abstract][Full Text] [Related]
4. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
5. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Gadde KM; Allison DB; Ryan DH; Peterson CA; Troupin B; Schwiers ML; Day WW
Lancet; 2011 Apr; 377(9774):1341-52. PubMed ID: 21481449
[TBL] [Abstract][Full Text] [Related]
6. A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
Bray GA; Hollander P; Klein S; Kushner R; Levy B; Fitchet M; Perry BH
Obes Res; 2003 Jun; 11(6):722-33. PubMed ID: 12805393
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
[TBL] [Abstract][Full Text] [Related]
8. Weight reduction effects of a black soy peptide supplement in overweight and obese subjects: double blind, randomized, controlled study.
Kwak JH; Ahn CW; Park SH; Jung SU; Min BJ; Kim OY; Lee JH
Food Funct; 2012 Oct; 3(10):1019-24. PubMed ID: 22739624
[TBL] [Abstract][Full Text] [Related]
9. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients.
Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R
Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343
[TBL] [Abstract][Full Text] [Related]
10. The effect of 6 months supplementation with conjugated linoleic acid on insulin resistance in overweight and obese.
Syvertsen C; Halse J; Høivik HO; Gaullier JM; Nurminiemi M; Kristiansen K; Einerhand A; O'Shea M; Gudmundsen O
Int J Obes (Lond); 2007 Jul; 31(7):1148-54. PubMed ID: 17031391
[TBL] [Abstract][Full Text] [Related]
11. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
[TBL] [Abstract][Full Text] [Related]
12. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1B
Digenio A; Pham NC; Watts LM; Morgan ES; Jung SW; Baker BF; Geary RS; Bhanot S
Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
[TBL] [Abstract][Full Text] [Related]
13. Beneficial effects of metformin in normoglycemic morbidly obese adolescents.
Kay JP; Alemzadeh R; Langley G; D'Angelo L; Smith P; Holshouser S
Metabolism; 2001 Dec; 50(12):1457-61. PubMed ID: 11735093
[TBL] [Abstract][Full Text] [Related]
14. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects.
Belza A; Frandsen E; Kondrup J
Int J Obes (Lond); 2007 Jan; 31(1):121-30. PubMed ID: 16652130
[TBL] [Abstract][Full Text] [Related]
15. Effect of orlistat in overweight poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study.
Kuo CS; Pei D; Yao CY; Hsieh MC; Kuo SW
Int J Clin Pract; 2006 Aug; 60(8):906-10. PubMed ID: 16893433
[TBL] [Abstract][Full Text] [Related]
16. Low-dose growth hormone treatment combined with diet restriction decreases insulin resistance by reducing visceral fat and increasing muscle mass in obese type 2 diabetic patients.
Nam SY; Kim KR; Cha BS; Song YD; Lim SK; Lee HC; Huh KB
Int J Obes Relat Metab Disord; 2001 Aug; 25(8):1101-7. PubMed ID: 11477493
[TBL] [Abstract][Full Text] [Related]
17. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
[TBL] [Abstract][Full Text] [Related]
18. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release.
Garvey WT; Ryan DH; Bohannon NJ; Kushner RF; Rueger M; Dvorak RV; Troupin B
Diabetes Care; 2014 Dec; 37(12):3309-16. PubMed ID: 25249652
[TBL] [Abstract][Full Text] [Related]
19. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Gravina A; Mereu R; Palumbo I; D'Angelo A; Cicero AF
Metabolism; 2009 Aug; 58(8):1059-66. PubMed ID: 19394976
[TBL] [Abstract][Full Text] [Related]
20. The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
Tremblay A; Chaput JP; Bérubé-Parent S; Prud'homme D; Leblanc C; Alméras N; Després JP
Eur J Clin Pharmacol; 2007 Feb; 63(2):123-34. PubMed ID: 17200837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
